Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients
Status:
RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
to observe the dose-limiting toxicity (DLT) of liposomal mitoxantrone hydrochloride injection combined with cytarabine and decitabine in the initial treatment of acute myeloid leukemia (AML), to explore the maximum tolerated dose (MTD) of the combined D-CMG regimen, and to evaluate its safety and efficacy
Phase:
PHASE1
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University